Optilume药物涂层球囊扩张治疗复杂性尿道狭窄的回顾性研究
单中心回顾性研究评估Optilume紫杉醇药物涂层球囊(DCB)扩张在复杂性尿道狭窄患者中的结局,复杂性定义为既往尿道成形术、盆腔放疗、阴茎段受累或长度>3 cm。88例中60例(68%)为复杂性狭窄,26例(43%)完成6个月膀胱镜随访,解剖成功率为73.1%(19/26;95%CI 54%-86%),与有利队列69.2%(9/13)无显著差异(P=1.00),与ROBUST III的75%基准亦无差异(χ2=0.05,P=.82;精确二项P=.48)。复杂性队列Qmax显著改善(6周时7.1-12.1 mL/s;P=.007),AUA症状评分下降,1年免于干预率为81.7%。
要点
- 复杂性尿道狭窄DCB扩张6个月解剖成功率为73.1%,与有利狭窄及ROBUST III基准无显著差异。
- 复杂性队列Qmax从7.1改善至12.1 mL/s(6周,P=.007),AUA症状评分下降。
- 1年免于干预率为81.7%,但样本量小且随访不完整,不能声称等效。
核心结论
- DCB扩张在复杂性尿道狭窄中显示出有希望的短期解剖和功能结局,但样本量小和随访不完整妨碍等效性结论。
研究设计与样本
- 单中心回顾性研究,纳入2022年至2025年接受DCB扩张的男性患者88例,其中复杂性狭窄60例(68%)。
- 复杂性狭窄定义:既往尿道成形术、盆腔放疗、阴茎段尿道受累或狭窄长度>3 cm。
- 主要终点为6个月膀胱镜解剖成功(0-1级复发,2-4级为失败)。
主要发现
- 复杂性队列26例完成6个月膀胱镜,解剖成功率为73.1%(19/26;95%CI 54%-86%)。
- 有利队列13例完成6个月膀胱镜,解剖成功率为69.2%(9/13),与复杂性队列比较P=1.00。
- 复杂性队列成功率与75%基准比较:χ2=0.05,P=.82;精确二项检验P=.48。
- 复杂性队列Qmax从7.1改善至12.1 mL/s(6周;P=.007),AUA症状评分下降。
- 1年免于干预率为81.7%。
临床怎么用
- 对于既往尿道成形术、放疗、阴茎段受累或长段狭窄的复杂性尿道狭窄患者,DCB扩张可作为短期改善排尿的选项。
- 术后6个月需行膀胱镜评估解剖成功,并监测Qmax和AUA症状评分。
- 需告知患者1年免于干预率约81.7%,且证据受限于小样本和随访不完整。
局限性
- 回顾性单中心设计,样本量小(复杂性队列仅26例完成6个月膀胱镜)。
- 随访不完整,仅43%的复杂性患者完成6个月膀胱镜评估。
- 不能声称与ROBUST III等效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate outcomes of Optilume paclitaxel drug-coated balloon (DCB) dilation in patients with "complex" urethral strictures, who were largely excluded from trials establishing its efficacy for short-segment bulbar strictures. METHODS: We retrospectively reviewed male patients undergoing DCB dilation at a single academic center between 2022 and 2025. "Complex" strictures were defined by prior urethroplasty, pelvic radiation, penile urethral involvement, or length >3 cm. The primary endpoint was anatomic success at 6 months, defined as grade 0-1 recurrence on cystoscopy (grade 2-4 = failure). Anatomic success was compared between cohorts (Fisher's exact test) and benchmarked against the 75% ROBUST III rate (one-sample chi-square and one-sided exact binomial tests). Secondary outcomes included AUA Symptom Score, maximum urinary flow rate (Qmax), and 1-year freedom from intervention. RESULTS: Of 88 patients, 60 (68%) had complex disease; 26 (43%) completed 6-month cystoscopy. Anatomic success was 73.1% (19/26; 95% CI 54%-86%) in the complex cohort vs 69.2% (9/13) in the favorable cohort (P = 1.00). The complex rate did not differ from the 75% benchmark (χ2 = 0.05, P = .82) and was not significantly lower (exact binomial P = .48). Qmax improved significantly in the complex cohort (7.1-12.1 mL/s at 6 weeks; P = .007), AUA-SS declined, and 1-year freedom from intervention was 81.7%. CONCLUSION: DCB dilation showed promising short-term anatomic and functional outcomes in complex stricture disease, though small sample size and incomplete follow-up preclude equivalence claims. Further evaluation is warranted to determine DCB efficacy.
引用
- Lence T, Desai T, Ivan S, et al. Still ROBUST: A Retrospective Study of Optilume Drug-Coated Balloon Dilation for Complex Urethral Stricture Disease. Urology. 2026. PMID: 42562269. doi:10.1016/j.urology.2026.07.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。